AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06387277 — intervention group
Intervention type: OTHER
Intervention: RV1551P GB3224
Description: RV1551P GB3224 Approximately 2 mg/cm² of product is applied to the Z1 or Z3 study areas (randomization).~From D1 to D2, a single product application is done at the study center by the subject in the presence of the clinical research technician (CRT) after epidermal ablation with an erbium YAG laser. After application, a dressing is placed on the measurement area and removed the following day at the center on D2 and D3 by the CRT before measurements.~From D3 to D18, two product applications are done with a minimum 4-hour interval:~* On visit days (D3, D5, D8, D10, D12, D15): an application is done at the study center by the subject in the presence of the CRT after measurements. A second application is done at home in the evening.~* On non-visit days (D4, D6, D7, D9, D11, D13, D14, D16, D17, D18): the subject applies 2 product applications at home (morning and evening).~Subjects receive the product at the end of visit 3 and return it at the last visit (visit 9).
Study NCT04694157 — intervention group
Intervention type: DEVICE
Intervention: cardiac shock wave therapy
Description: Two target segments of left ventricle will be chosen for all participants. In each target segment, 9 sties will be administered with 200 shots at each site. Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
Study NCT04629976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCO-48 Fumarate 4 mg
Description: 2 x 2mg NCO-48 Fumarate over 28 days of therapy
Study NCT04629976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCO-48 Fumarate 20 mg
Description: 2 x 10 mg NCO-48 Fumarate over 28 days of therapy
Study NCT04629976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Alafenamide 25 mg
Description: 25 mg over 28 days of therapy
Study NCT06507228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NWL PEBBLE STT
Description: At home testing for OSA with AcuPebble.
Study NCT06005038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pSOPT
Description: computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)
Study NCT06005038 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MLA
Description: computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.
Study NCT05537506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bracket slot 0.018
Description: That includes12 patients who will be treated using the bracket slot 0.018×0.025-inch system.
Study NCT05537506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bracket slot 0.022
Description: Includes12 patients who will be treated using the bracket slot 0.022×0.028-inch system
Study NCT05104788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Oral
Study NCT05104788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
Study NCT05104788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles
Study NCT05104788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
Study NCT06482255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy and therapeutic exercise
Description: * Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise
Study NCT06482255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy and therapeutic exercise and virtual reality
Description: * Soft tissue massage~* Mobilization of the glenohumeral joint~* Scapular retraining Therapeutic Exercise~* virtual reality
Study NCT06158256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary apnoea
Description: Series of static apneas at low lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds until completing the 6 minutes.
Study NCT04998292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezo-surgery with low level laser therapy
Description: Low level laser therapy
Study NCT05398224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
Description: Induction therapy: Zanubrutinib will be given as 160mg bid orally between days 1 and 14 of each 14-day cycle; rituximab will be given at 375mg/m2 intravenously on day 1 of each cycle; methotrexate at 3.5g/m2 for patients ≤65 or 1.5g/m2 for patients >65 (standard hydration/leucovorin support) will be given intravenously on day 2 of each 14-day cycle; for 6 cycles.~Consolidation therapy: For patients ≤65, autologous hematopoietic stem cell transplantation (ASCT with a conditioning regimen of thiotepa/carmustine) will be given as consolidation treatment after induction therapy.~Maintenance therapy:Drug: zanubrutinib. Zanubrutinib will be given as 160mg bid orally continuously until progression of the disease (PD), intolerable toxicity, death, or patient/investigator discretion.
Study NCT05591872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LD+I+TRB
Description: Same as in the arm description
Study NCT06403124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Description: Open reduction and internal fixation by reconstruction plate and screws
Study NCT04998292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Piezo-surgery only
Description: Piezo-surgery only
Study NCT06247449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain imaging
Description: Brain Magnetic resonance (or computed tomography if magnetic resonance is contraindicated)
Study NCT06247449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis of circulating tumor DNA
Description: One single blood draw for analysis of circulating tumor DNA
Study NCT06247449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testing Morbidities Index
Description: Questionnaire regarding the participant's perception of brain imaging.
Study NCT05288244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
Description: To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
Study NCT05288244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
Description: To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
Study NCT05288244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
Description: To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
Study NCT04294862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: TNP-2092 for injection 100mg/vial
Study NCT05141136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound probe sagittal group
Description: Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.
Study NCT05141136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound probe transverse group
Description: Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.
Study NCT06109493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
Study NCT06552065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collagen with silk fibroin membrane
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.~An immediate implant with collagen membrane ( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures
Study NCT06552065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collagen with silk fibroin membrane
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.~An immediate implant with collagen membrane ( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures
Study NCT06552065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cross linked collagen membrane
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.
Study NCT06552065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cross linked collagen membrane
Description: A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.
Study NCT06551441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: The HIIT intervention consist of 4 intervals with each lasting 4 minutes (4x4min). If a participant reports discomfort related to the length of the intervals or start to feel unmotivated by performing the same exercise, we will use another HIIT protocol: 10x1min.~The 4x4min HIIT consists of a warm-up period of 10 minutes with a target heart rate at 60-70% of HRmax, followed by 4 HIIT intervals with a target HR ≥85%. The intervals are separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following this, a cool down period of three minutes at warm up intensity is performed.~The 10x1min HIIT consists of a 10-minute warm-up period.The warm-up is followed by 10 intervals, each lasting 1 min at 100% of maximal workload, separated by three minutes of active rest, in which the HR should drop to 60% of maximum. Following the intervals, a cool down period of three minutes at warm up intensity is performed.
Study NCT05108961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: one session with precise acupunture points
Study NCT05108961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A digital stress scale
Description: The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)
Study NCT05108961 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: A digital stress scale
Description: The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)
Study NCT05108961 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: A digital stress scale
Description: The digital stress scale before and after the session: Oral digital scale. The doctor asks the participant to quantify their anxiety on a virtual scale ranging from 0 (absent anxiety) to 10 (maximum anxiety imaginable)
Study NCT05108961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a relaxation questionnaire
Description: The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale
Study NCT05108961 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: a relaxation questionnaire
Description: The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale
Study NCT05108961 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: a relaxation questionnaire
Description: The Global Relaxation Questionnaire after the session: Dovero Global Relaxation Scale
Study NCT05108961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bispectral Index
Description: BIS is based on an EEG analysis algorithm
Study NCT05108961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Bispectral Index
Description: BIS is based on an EEG analysis algorithm
Study NCT05108961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Bispectral Index
Description: BIS is based on an EEG analysis algorithm
Study NCT05295940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3841136
Description: Administered SC.
Study NCT05295940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT04605185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib Tosilate Tablets
Description: 100mg Qd/150mg Qd/100mg Bid, po
Study NCT04605185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: 240 mg, iv drip,q3w
Study NCT06619769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSense-Cancer CBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer
Description: eSense-Cancer CBT is an online, cognitive behavioural therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer CBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
Study NCT06619769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Navigator support for eSense-Cancer
Description: The eSense digital health tool has been previously tested alongside the support of treatment navigators - trained undergraduate students, not licensed therapists, who provide encouragement and answer any questions users may have as they work through eSense.
Study NCT06619769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: eSense-Cancer MBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer
Description: eSense-Cancer MBT is an online, mindfulness-based therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer MBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
Study NCT06627491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagined muscle contractions
Description: The intervention involved imagining, with no physical movement, of muscle contractions.
Study NCT06632561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Description: Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months
Study NCT06632561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pills one tablet daily for 6 months
Study NCT06273839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)
Study NCT06273839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 70 mg free acid tablet (Test 1)
Description: Tafamidis 61 mg free acid tablet (Test 1)
Study NCT06273839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis 61 mg free acid capsule (Reference)
Description: Tafamidis 61 mg free acid capsule (Reference)
Study NCT04620421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythm-based Multitask Training
Description: Participants will be assigned to a weekly one-hour RYMA session for six months, followed by a six-month follow-up period without training. An experienced instructor will perform the RYMA sessions, which consists of a wide variety of rhythm-based multitask exercises performed to improvised piano music. The RYMA intervention is inspired by Dalcroze eurhythmics and exercises consists of components such as 1) coordination between hands and/or feet, 2) dissociation between hands and/or feet, 3) movements based on musical cues (e.g. follow the tempo), 4) movement inhibition based on musical cues, 5) handling of props (e.g. balls, scarfs, and plates), 6) pair or group-based coordination movements (e.g. clapping each other's hands and mirroring movements), 7) memorizing and repeating of rhythmic patterns, and 8) quick motoric responses to unexpected cues.
Study NCT05271994 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopic biliary drainage
Description: endoscopic biliary drainage
Study NCT06509412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LANAP surgical protocol using ND:YAG 1064 laser
Description: A free running pulsed, 1064 nm wavelength-specific ND:YAG laser (Light walker AT)\* with an attached 320 µm diameter optical glass fiber attached to a metallic hand piece with a flexible tip, which will be set at 3:4 -watt average power, 20 HZ, and a 100-600 µs pulse duration
Study NCT06509412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LANAP surgical protocol using diode 940 laser
Description: Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm was attached with a power average set at 0.5-1 watt, in continuous mode, and 20 HZ
Study NCT06509412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing (SRP)
Description: Scaling and root planing (SRP) using ultrasonic device (Woodpecker USD-P Led Ultrasonic Scaler Ende) at moderate setting and with appropriate tips and also hand curettes will be used for root planning.
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06639074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM
Study NCT06639074 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06639074 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06639074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Description: Given ID
Study NCT06639074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given ID
Study NCT06639074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and Diphtheria Toxoids Adsorbed
Description: Given IM
Study NCT06639074 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tetanus and Diphtheria Toxoids Adsorbed
Description: Given IM